Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Kertes, Jennifer; Gez, Sharon Baruch; Saciuk, Yaki; Supino-Rosin, Lia; Stein, Naama Shamir; Mizrahi-Reuveni, Miri; Zohar, Anat E.

doi:10.3201/eid2802.211834

i

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Supporting Files Public Domain

2 2022
By Kertes, Jennifer ; Gez, Sharon Baruch ; Saciuk, Yaki ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Kertes, Jennifer ; Gez, Sharon Baruch ; Saciuk, Yaki ; Supino-Rosin, Lia ; Stein, Naama Shamir ; Mizrahi-Reuveni, Miri ; Zohar, Anat E.
Description:

Israel experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decrease over time, describe the relationship between IgG titer and subsequent PCR-confirmed infection, and compare PCR-confirmed infection rates by period of vaccination. Mean IgG levels steadily decreased over the 6-month period in the total tested population and in all age groups. An inverse relationship was found between IgG titer and subsequent PCR-positive infection. Persons vaccinated during the first 2 months of the campaign were more likely to become infected than those subsequently vaccinated. The vaccinated group >60 years of age had lower initial IgG levels and were at greater risk for infection. The findings support the decision to add a booster vaccine for persons >60 years of age.
Subjects:

Bnt162 Vaccine Coronavirus Disease Coronaviruses Covid-19 Covid-19 Vaccines Effectiveness Of Mrna Bnt162B2 Vaccine 6 Months After Vaccination Among Patients In Large Health Maintenance Organization, Israel Epidemiology Expedited Health Maintenance Organization Health Maintenance Organizations Hmo Humans Immune Response Infections Israel Mrna Bnt162B2 Vaccine Public Health Research Respiratory Infections Rna, Messenger Sars-Cov-2 Serologic Tests Vaccination Vaccines Viruses Zoonoses
Source:

Emerg Infect Dis. 2022; 28(2):338-346
Pubmed ID:

34906291
Pubmed Central ID:

PMC8798683
Document Type:

Journal Article
Volume:

28
Issue:

2
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:8d8e8d83540f636106b535957947500a44f647e50cb6787bd3e66d0ee19b1139
Download URL:

https://stacks.cdc.gov/view/cdc/114553/cdc_114553_DS1.pdf
File Type:

[PDF - 1.16 MB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.